psma-negative (psma−) pc3-flu (Johns Hopkins HealthCare)
90
Structured Review
Johns Hopkins HealthCare
psma-negative (psma−) pc3-flu
a in PC3-PIP and PC3-flu Tumor-Bearing Balb/c Nude Mice at 1, 2, and 24 h p.i. of [ 177 Lu]Lu-P17" width="250" height="auto" />
Psma Negative (Psma−) Pc3 Flu, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pc3+flu+(psma)/pc3+pip+cell+line/pmc11865982-258-20-26
Average 90 stars, based on 1 article reviews
a in Psma Negative (Psma−) Pc3 Flu, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pc3+flu+(psma)/pc3+pip+cell+line/pmc11865982-258-20-26
Average 90 stars, based on 1 article reviews
psma-negative (psma−) pc3-flu - by Bioz Stars,
2026-10
90/100 stars
Images
1) Product Images from "Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions"
Article Title: Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions
Journal: ACS Omega
doi: 10.1021/acsomega.4c10142
a in PC3-PIP and PC3-flu Tumor-Bearing Balb/c Nude Mice at 1, 2, and 24 h p.i. of [ 177 Lu]Lu-P17" title="Biodistribution Figure Legend Snippet: Biodistribution
Techniques Used:
a in PC3-PIP and PC3-flu Tumor-Bearing Balb/c Nude Mice at 1, 2, and 24 h p.i. of [ 177 Lu]Lu-P18" title="Biodistribution Figure Legend Snippet: Biodistribution
Techniques Used:
a in PC3-PIP and PC3-flu Tumor-Bearing Balb/c Nude Mice at 1, 2, and 24 h p.i. of [ 177 Lu]Lu-PSMA-617" title="Biodistribution Figure Legend Snippet: Biodistribution
Techniques Used:
Related Articles
Optical Imaging:Article Title: Comparison of the Effects of DOTA and NOTA Chelators on 64 Cu-Cudotadipep and 64 Cu-Cunotadipep for Prostate Cancer. Article Snippet: The Article Title: 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents Article Snippet: Six- to eight-week-old male, Article Title: PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer Article Snippet: Article Title: A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation Article Snippet: The Article Title: A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents Article Snippet: For optical imaging studies and Article Title: Silicon phthalocyanines functionalized with axial substituents targeting PSMA: synthesis and preliminary assessment of their potential for PhotoDynamic Therapy of prostate cancer. Article Snippet: Photodynamic therapy (PDT) is a clinical modality based on the irradiation of different diseases, mostly tumours, with light following the selective uptake of a photosensitiser by the pathological tissue.. In this study, two new silicon(IV)phtalocyanines (SiPcs) functionalized at both axial positions with a PSMA inhibitors are reported as candidate photosensitizers for PDT of prostate cancer, namely compounds SiPc-PQ(PSMAi)2 and SiPc-OSi(PSMAi)2.. These compounds share the same PSMA-binding motif, but differ in the linker that connects the inhibitor moiety to the Si(IV) atom: an alkoxy (Si-O-C) bond for SiPc-PQ(PSMAi)2, and a silyloxy (Si-O-Si) bond for SiPc-OSi(PSMAi)2. Article Title: Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions Article Snippet: In Ex Vivo:Article Title: Comparison of the Effects of DOTA and NOTA Chelators on 64 Cu-Cudotadipep and 64 Cu-Cunotadipep for Prostate Cancer. Article Snippet: The Article Title: 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents Article Snippet: Six- to eight-week-old male, Article Title: PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer Article Snippet: Article Title: A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation Article Snippet: The Article Title: A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents Article Snippet: For optical imaging studies and Article Title: Silicon phthalocyanines functionalized with axial substituents targeting PSMA: synthesis and preliminary assessment of their potential for PhotoDynamic Therapy of prostate cancer. Article Snippet: Photodynamic therapy (PDT) is a clinical modality based on the irradiation of different diseases, mostly tumours, with light following the selective uptake of a photosensitiser by the pathological tissue.. In this study, two new silicon(IV)phtalocyanines (SiPcs) functionalized at both axial positions with a PSMA inhibitors are reported as candidate photosensitizers for PDT of prostate cancer, namely compounds SiPc-PQ(PSMAi)2 and SiPc-OSi(PSMAi)2.. These compounds share the same PSMA-binding motif, but differ in the linker that connects the inhibitor moiety to the Si(IV) atom: an alkoxy (Si-O-C) bond for SiPc-PQ(PSMAi)2, and a silyloxy (Si-O-Si) bond for SiPc-OSi(PSMAi)2. Article Title: Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions Article Snippet: In Imaging:Article Title: Comparison of the Effects of DOTA and NOTA Chelators on 64 Cu-Cudotadipep and 64 Cu-Cunotadipep for Prostate Cancer. Article Snippet: The Article Title: 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents Article Snippet: Six- to eight-week-old male, Article Title: PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer Article Snippet: Article Title: A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation Article Snippet: The Article Title: A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents Article Snippet: For optical imaging studies and Article Title: Silicon phthalocyanines functionalized with axial substituents targeting PSMA: synthesis and preliminary assessment of their potential for PhotoDynamic Therapy of prostate cancer. Article Snippet: Photodynamic therapy (PDT) is a clinical modality based on the irradiation of different diseases, mostly tumours, with light following the selective uptake of a photosensitiser by the pathological tissue.. In this study, two new silicon(IV)phtalocyanines (SiPcs) functionalized at both axial positions with a PSMA inhibitors are reported as candidate photosensitizers for PDT of prostate cancer, namely compounds SiPc-PQ(PSMAi)2 and SiPc-OSi(PSMAi)2.. These compounds share the same PSMA-binding motif, but differ in the linker that connects the inhibitor moiety to the Si(IV) atom: an alkoxy (Si-O-C) bond for SiPc-PQ(PSMAi)2, and a silyloxy (Si-O-Si) bond for SiPc-OSi(PSMAi)2. Article Title: Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions Article Snippet: In Injection:Article Title: Comparison of the Effects of DOTA and NOTA Chelators on 64 Cu-Cudotadipep and 64 Cu-Cunotadipep for Prostate Cancer. Article Snippet: The Article Title: 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents Article Snippet: Six- to eight-week-old male, Article Title: PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer Article Snippet: Article Title: A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation Article Snippet: The Article Title: A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents Article Snippet: For optical imaging studies and Article Title: Silicon phthalocyanines functionalized with axial substituents targeting PSMA: synthesis and preliminary assessment of their potential for PhotoDynamic Therapy of prostate cancer. Article Snippet: Photodynamic therapy (PDT) is a clinical modality based on the irradiation of different diseases, mostly tumours, with light following the selective uptake of a photosensitiser by the pathological tissue.. In this study, two new silicon(IV)phtalocyanines (SiPcs) functionalized at both axial positions with a PSMA inhibitors are reported as candidate photosensitizers for PDT of prostate cancer, namely compounds SiPc-PQ(PSMAi)2 and SiPc-OSi(PSMAi)2.. These compounds share the same PSMA-binding motif, but differ in the linker that connects the inhibitor moiety to the Si(IV) atom: an alkoxy (Si-O-C) bond for SiPc-PQ(PSMAi)2, and a silyloxy (Si-O-Si) bond for SiPc-OSi(PSMAi)2. Article Title: Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions Article Snippet: In Expressing:Article Title: Comparison of the Effects of DOTA and NOTA Chelators on 64 Cu-Cudotadipep and 64 Cu-Cunotadipep for Prostate Cancer. Article Snippet: The Article Title: 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents Article Snippet: Six- to eight-week-old male, Article Title: PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer Article Snippet: Article Title: A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation Article Snippet: The Article Title: A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents Article Snippet: For optical imaging studies and Article Title: Silicon phthalocyanines functionalized with axial substituents targeting PSMA: synthesis and preliminary assessment of their potential for PhotoDynamic Therapy of prostate cancer. Article Snippet: Photodynamic therapy (PDT) is a clinical modality based on the irradiation of different diseases, mostly tumours, with light following the selective uptake of a photosensitiser by the pathological tissue.. In this study, two new silicon(IV)phtalocyanines (SiPcs) functionalized at both axial positions with a PSMA inhibitors are reported as candidate photosensitizers for PDT of prostate cancer, namely compounds SiPc-PQ(PSMAi)2 and SiPc-OSi(PSMAi)2.. These compounds share the same PSMA-binding motif, but differ in the linker that connects the inhibitor moiety to the Si(IV) atom: an alkoxy (Si-O-C) bond for SiPc-PQ(PSMAi)2, and a silyloxy (Si-O-Si) bond for SiPc-OSi(PSMAi)2. Article Title: Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions Article Snippet: In Fluorescence:Article Title: Comparison of the Effects of DOTA and NOTA Chelators on 64 Cu-Cudotadipep and 64 Cu-Cunotadipep for Prostate Cancer. Article Snippet: The Article Title: 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents Article Snippet: Six- to eight-week-old male, Article Title: PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer Article Snippet: Article Title: A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation Article Snippet: The Article Title: A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents Article Snippet: For optical imaging studies and Article Title: Silicon phthalocyanines functionalized with axial substituents targeting PSMA: synthesis and preliminary assessment of their potential for PhotoDynamic Therapy of prostate cancer. Article Snippet: Photodynamic therapy (PDT) is a clinical modality based on the irradiation of different diseases, mostly tumours, with light following the selective uptake of a photosensitiser by the pathological tissue.. In this study, two new silicon(IV)phtalocyanines (SiPcs) functionalized at both axial positions with a PSMA inhibitors are reported as candidate photosensitizers for PDT of prostate cancer, namely compounds SiPc-PQ(PSMAi)2 and SiPc-OSi(PSMAi)2.. These compounds share the same PSMA-binding motif, but differ in the linker that connects the inhibitor moiety to the Si(IV) atom: an alkoxy (Si-O-C) bond for SiPc-PQ(PSMAi)2, and a silyloxy (Si-O-Si) bond for SiPc-OSi(PSMAi)2. Article Title: Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions Article Snippet: In Immunohistochemistry:Article Title: Comparison of the Effects of DOTA and NOTA Chelators on 64 Cu-Cudotadipep and 64 Cu-Cunotadipep for Prostate Cancer. Article Snippet: The Article Title: 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents Article Snippet: Six- to eight-week-old male, Article Title: PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer Article Snippet: Article Title: A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation Article Snippet: The Article Title: A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents Article Snippet: For optical imaging studies and Article Title: Silicon phthalocyanines functionalized with axial substituents targeting PSMA: synthesis and preliminary assessment of their potential for PhotoDynamic Therapy of prostate cancer. Article Snippet: Photodynamic therapy (PDT) is a clinical modality based on the irradiation of different diseases, mostly tumours, with light following the selective uptake of a photosensitiser by the pathological tissue.. In this study, two new silicon(IV)phtalocyanines (SiPcs) functionalized at both axial positions with a PSMA inhibitors are reported as candidate photosensitizers for PDT of prostate cancer, namely compounds SiPc-PQ(PSMAi)2 and SiPc-OSi(PSMAi)2.. These compounds share the same PSMA-binding motif, but differ in the linker that connects the inhibitor moiety to the Si(IV) atom: an alkoxy (Si-O-C) bond for SiPc-PQ(PSMAi)2, and a silyloxy (Si-O-Si) bond for SiPc-OSi(PSMAi)2. Article Title: Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions Article Snippet: In Staining:Article Title: Comparison of the Effects of DOTA and NOTA Chelators on 64 Cu-Cudotadipep and 64 Cu-Cunotadipep for Prostate Cancer. Article Snippet: The Article Title: 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents Article Snippet: Six- to eight-week-old male, Article Title: PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer Article Snippet: Article Title: A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation Article Snippet: The Article Title: A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents Article Snippet: For optical imaging studies and Article Title: Silicon phthalocyanines functionalized with axial substituents targeting PSMA: synthesis and preliminary assessment of their potential for PhotoDynamic Therapy of prostate cancer. Article Snippet: Photodynamic therapy (PDT) is a clinical modality based on the irradiation of different diseases, mostly tumours, with light following the selective uptake of a photosensitiser by the pathological tissue.. In this study, two new silicon(IV)phtalocyanines (SiPcs) functionalized at both axial positions with a PSMA inhibitors are reported as candidate photosensitizers for PDT of prostate cancer, namely compounds SiPc-PQ(PSMAi)2 and SiPc-OSi(PSMAi)2.. These compounds share the same PSMA-binding motif, but differ in the linker that connects the inhibitor moiety to the Si(IV) atom: an alkoxy (Si-O-C) bond for SiPc-PQ(PSMAi)2, and a silyloxy (Si-O-Si) bond for SiPc-OSi(PSMAi)2. Article Title: Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions Article Snippet: In Control:Article Title: Comparison of the Effects of DOTA and NOTA Chelators on 64 Cu-Cudotadipep and 64 Cu-Cunotadipep for Prostate Cancer. Article Snippet: The Article Title: 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents Article Snippet: Six- to eight-week-old male, Article Title: PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer Article Snippet: Article Title: A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation Article Snippet: The Article Title: A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents Article Snippet: For optical imaging studies and Article Title: Silicon phthalocyanines functionalized with axial substituents targeting PSMA: synthesis and preliminary assessment of their potential for PhotoDynamic Therapy of prostate cancer. Article Snippet: Photodynamic therapy (PDT) is a clinical modality based on the irradiation of different diseases, mostly tumours, with light following the selective uptake of a photosensitiser by the pathological tissue.. In this study, two new silicon(IV)phtalocyanines (SiPcs) functionalized at both axial positions with a PSMA inhibitors are reported as candidate photosensitizers for PDT of prostate cancer, namely compounds SiPc-PQ(PSMAi)2 and SiPc-OSi(PSMAi)2.. These compounds share the same PSMA-binding motif, but differ in the linker that connects the inhibitor moiety to the Si(IV) atom: an alkoxy (Si-O-C) bond for SiPc-PQ(PSMAi)2, and a silyloxy (Si-O-Si) bond for SiPc-OSi(PSMAi)2. Article Title: Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions Article Snippet: In Comparison:Article Title: Comparison of the Effects of DOTA and NOTA Chelators on 64 Cu-Cudotadipep and 64 Cu-Cunotadipep for Prostate Cancer. Article Snippet: The Article Title: 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents Article Snippet: Six- to eight-week-old male, Article Title: PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer Article Snippet: Article Title: A Novel PSMA-Targeted Probe for NIRF-Guided Surgery and Photodynamic Therapy: Synthesis and Preclinical Validation Article Snippet: The Article Title: A Series of PSMA-Targeted Near-Infrared Fluorescent Imaging Agents Article Snippet: For optical imaging studies and Article Title: Silicon phthalocyanines functionalized with axial substituents targeting PSMA: synthesis and preliminary assessment of their potential for PhotoDynamic Therapy of prostate cancer. Article Snippet: Photodynamic therapy (PDT) is a clinical modality based on the irradiation of different diseases, mostly tumours, with light following the selective uptake of a photosensitiser by the pathological tissue.. In this study, two new silicon(IV)phtalocyanines (SiPcs) functionalized at both axial positions with a PSMA inhibitors are reported as candidate photosensitizers for PDT of prostate cancer, namely compounds SiPc-PQ(PSMAi)2 and SiPc-OSi(PSMAi)2.. These compounds share the same PSMA-binding motif, but differ in the linker that connects the inhibitor moiety to the Si(IV) atom: an alkoxy (Si-O-C) bond for SiPc-PQ(PSMAi)2, and a silyloxy (Si-O-Si) bond for SiPc-OSi(PSMAi)2. Article Title: Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions Article Snippet: In |
